​

ImageneBio (IMA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

IMA Stock Forecast

ImageneBio (IMA) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $1.33, with a high of $1.33 and a low of $1.33. This represents a -78.51% decline from the last price of $6.19.

IMA Stock Rating

ImageneBio stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

IMA Price Target Upside V Benchmarks

TypeNameUpside
StockImageneBio-78.51%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$6.19$6.19$6.19
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-2-1-3
Nov, 25-2---2
Oct, 25-1---1
Sep, 25-1---1
Aug, 25-1---1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 29, 2024David NierengartenWedbush$1.33$1.64-18.90%-78.51%
May 29, 2024David NierengartenWedbush$2.00$1.3350.38%-67.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 25, 2025WedbushNeutralUnderperformdowngrade
May 29, 2024William BlairOutperformOutperformhold
May 29, 2024Cowen & Co.BuyBuyhold
May 29, 2024Wells FargoUnderweightdowngrade
May 29, 2024WedbushOutperformNeutraldowngrade
May 29, 2024H.C. WainwrightBuyBuyhold
May 14, 2024WedbushBuyOutperforminitialise
Mar 19, 2024WedbushBuyBuyhold
Jan 19, 2024WedbushOutperformOutperformhold
Sep 22, 2023WedbushOutperforminitialise

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-1.63$-1.02-----
Avg Forecast$-19.48$-13.29$-2.95$-3.32$-6.12$-7.24$-5.41
High Forecast$-19.48$-13.29$-0.87$-3.32$-6.12$-7.24$-5.41
Low Forecast$-19.48$-13.29$-5.03$-3.32$-6.12$-7.24$-5.41
Surprise %-91.63%-92.33%-----

Revenue Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$9.16M------
Avg Forecast$11.87M$3.50M-----
High Forecast$11.87M$3.50M-----
Low Forecast$11.87M$3.50M-----
Surprise %-22.84%------

Net Income Forecast

$-950M $-760M $-570M $-380M $-190M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-68.17M$-49.23M-----
Avg Forecast$-940.12M$-641.23M$-142.56M$-160.16M$-295.50M$-349.39M$-261.08M
High Forecast$-940.12M$-641.23M$-41.75M$-160.16M$-295.50M$-349.39M$-261.08M
Low Forecast$-940.12M$-641.23M$-242.94M$-160.16M$-295.50M$-349.39M$-261.08M
Surprise %-92.75%-92.32%-----

IMA Forecast FAQ

Is ImageneBio stock a buy?

ImageneBio stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ImageneBio is a favorable investment for most analysts.

What is ImageneBio's price target?

ImageneBio's price target, set by 5 Wall Street analysts, averages $1.33 over the next 12 months. The price target range spans from $1.33 at the low end to $1.33 at the high end, suggesting a potential -78.51% change from the previous closing price of $6.19.

How does ImageneBio stock forecast compare to its benchmarks?

ImageneBio's stock forecast shows a -78.51% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for ImageneBio over the past three months?

  • December 2025: 0% Strong Buy, 66.67% Buy, 0% Hold, 33.33% Sell, 0% Strong Sell.
  • November 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ImageneBio’s EPS forecast?

ImageneBio's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.95, marking a 189.22% increase from the reported $-1.02 in 2024. Estimates for the following years are $-3.32 in 2026, $-6.12 in 2027, $-7.24 in 2028, and $-5.41 in 2029.

What is ImageneBio’s revenue forecast?

ImageneBio's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $0 for 2027, $0 for 2028, and $0 for 2029.

What is ImageneBio’s net income forecast?

ImageneBio's net income forecast for the fiscal year ending in December 2025 stands at $-143M, representing an 189.55% increase from the reported $-49.234M in 2024. Projections indicate $-160M in 2026, $-296M in 2027, $-349M in 2028, and $-261M in 2029.